[go: up one dir, main page]

WO1999002194A1 - Procedes et systemes pour la preparation et le scellage de structures produisant un rayonnement - Google Patents

Procedes et systemes pour la preparation et le scellage de structures produisant un rayonnement Download PDF

Info

Publication number
WO1999002194A1
WO1999002194A1 PCT/US1998/014489 US9814489W WO9902194A1 WO 1999002194 A1 WO1999002194 A1 WO 1999002194A1 US 9814489 W US9814489 W US 9814489W WO 9902194 A1 WO9902194 A1 WO 9902194A1
Authority
WO
WIPO (PCT)
Prior art keywords
radioactive
radioactive material
substrate material
bonding
implantable
Prior art date
Application number
PCT/US1998/014489
Other languages
English (en)
Inventor
Robert A. Stern
Shigemasa Osaki
Original Assignee
Innerdyne, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innerdyne, Inc. filed Critical Innerdyne, Inc.
Priority to EP98934491A priority Critical patent/EP0998309A1/fr
Priority to JP2000501784A priority patent/JP2001509493A/ja
Priority to AU83999/98A priority patent/AU8399998A/en
Publication of WO1999002194A1 publication Critical patent/WO1999002194A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N5/1002—Intraluminal radiation therapy

Definitions

  • the present invention relates generally to methods and systems for preparing radiation delivery devices, such as stents, catheters, and the like.
  • the present invention relates to a method for coating a radioactive material onto a surface of the delivery device.
  • Cardiovascular disease is a major cause of death and disability in the United States and throughout the world.
  • PCTA percutaneous translumenal angioplasty
  • a catheter having an expansible distal end usually in the form of an inflatable balloon, is positioned within a blood vessel at a stenotic site.
  • the expansible end is expanded to dilate the vessel to restore adequate blood flow beyond the diseased region.
  • Other intravascular techniques for restoring blood flow include atherectomy where a cutting blade or other mechanical device is used to remove stenotic material, laser angioplasty where laser energy is used to ablate stenotic material, and the like.
  • An alternative approach for inhibiting hyperplasia involves the exposure of the treated blood vessel to radioactivity. It is well known that radioactivity inhibits cell proliferation in view of in vi tro cell culture and it has been found that intravascular exposure of a treated blood vessel to low levels of radiation will indeed inhibit hyperplasia and subsequent restenosis.
  • the preparation of radioactive stents is problematic in a number of respects.
  • the stents are desirably formed from radioactive materials having a relatively short half-life. It is undesirable to implant a radioactive material having a long half-life within a patient's vasculature.
  • stents may be readily fabricated from such radioactive materials, such as irradiated alloys, the stents so prepared will have a very limited shelf life. That is, once the stent has been fabricated, e.g. by irradiation or by plating, its useful life is limited. Thus, for stents fabricated at a central facility, distribution and inventory maintenance become significant problems.
  • Stents have been made radioactive by irradiating them in cyclotrons or coating them with a 32P plasma.
  • the cyclotron method requires very expensive equipment that has limited capacities. Producing a plasma of 32P resulting in an aerosol of 32P that poses potential health risks to the production personnel.
  • the stent has been fabricated by irradiation or plating, its useful life is limited. Thus, for stents fabricated at a central facility, distribution and inventory maintenance become significant problems. To control the delivered radiation dose, such stents must be fabricated, shipped and delivered within a narrow clinical time frames. For these reasons, it would be desirable to provide improved methods and devices for the delivery of radioactivity to patients for therapeutic purposes.
  • the methods should be useful with permanently implanted devices, such as vascular stents, grafts, and coils; temporarily implanted devices, such as catheters, wires, and pellets; and biodegradable implants and materials, such as beads, particles, gels, and the like.
  • the fabrication and preparation methods should be convenient, economical, capable of being performed in hospitals and other user facilities, and capable of incorporating radioactive materials having the appropriate dosages for treating hyperplasia and other disease conditions. At least some of these objectives will be met by various embodiments of the present invention described below.
  • U.S. Patent No. 5,338,770 describes methods and materials for coating biomedical devices and implants with poly (ethylene oxide) chains suitable for covalent attachment of bioactive molecules intended to counteract blood-material incompatibility.
  • EP 706 784 describes a stent having a carrier material for a therapeutic material, such as a radioactive substance.
  • U.S. Patent No. 5,463,010 describes membranes, including polymerized aliphatic hydrocyclosiloxane monomers, for use in coating biomedical devices and implants, and suitable for use as a substrate for covalent attachment of other molecules.
  • patents describe various methods for labeling of substrates, typically peptides, proteins and the like, with radioactive metal ions, such as use of DTPA chelates in U.S. Patent Nos . 4,479,930 and 4,668,503; U.S. Patent No. 5,371,184, in which a chelate ligand is disclosed for labeling hirudin receptor-specific peptides; U.S. Patent No. 4,732,864, in which the use of metallothionein or metallothionein fragments conjugated to biologically active molecules is disclosed; U.S. Patent No.
  • the present invention permits the radioactive material to be incorporated onto the implantable device or material at a predictable, usually immediate, time before use.
  • the radioactive substances which are bonded to the device may be prepared at a central manufacturing location on a regular basis, e.g. daily, or in some cases may be fabricated on-site so that in either case fresh radioactive substance having a known radioactivity or radioactive dosage may be employed.
  • the methods, devices, and materials of the present invention permit very accurate control of radioactive dosages and provide a number of advantages including that they can be used independent of surgery as a curative therapy for many types of stenosis and neoplastic diseases; they can extend the role of stents in achieving local control of restenosis; they can provide an accurate method of controlling the delivery of radiation (dosage) to a diseased area and minimally affect the normal surrounding tissue; they can be used with drug therapy including anti-platelet medications; side-effects from treatment may be kept to a minimum; radiation exposure to nurses, hospital staff and family members is reduced or eliminated; and the required hospital stay is minimized and in some cases eliminated (the procedure may be done on an outpatient basis) .
  • a method for coating an implantable device or material with a radioactive substance comprises providing an implantable device or material having a surface, referred to collectively below as "structures.” At least a portion of the surface has been coated with a substrate material, and a radioactive material is bonded to the substrate material to provide a coated device.
  • the implantable structures can be intended for permanent or temporary implantation, with exemplary devices including stents, coils, wires, inflatable balloons, needles, probes, catheters, and the like, and exemplary methods including beads, particles, gels, and the like. Such structures may be delivered by or incorporated into or onto intravascular and other medical catheters and devices .
  • the substrate material will be selected to adhere to the surface of the implantable structure and to provide a bonding situs for subsequent attachment of the radioactive material.
  • the substrate material may be bifunctional , with a first moiety or functionality being capable of covalent or non-covalent attachment to the structure surface and a second moiety or functionality being available for bonding to the radioactive material, and optionally including a linking portion therebetween.
  • the radioactive material will include a radionuclide, and preferably a radioactive metal ion, such as radioisotopes of rhenium, but may include radioactive metal ions found in the group consisting of elements 26-30 (Fe, Co, Ni , Cu, Zn) , 33-34 (As, Se) , 42-50 (Mo, Tc, Ru, Rh, Pd, Ag, Cd, In, Sn) and 75-85 (Re, Os, Ir, Pt , Au, Hg, Tl , Pb, Bi, Po, At), and particularly the radionuclides 62 Cu, ⁇ 4 Cu, 67 Cu, 97 Ru, 105 Rh, 109 Pd, 186 Re, 188 Re, 198 Au, 199 Au, 203 Pb, 211 Pb and 212 Bi.
  • a radioactive metal ion such as radioisotopes of rhenium
  • radioactive metal ions found in the group consisting of elements 26-30 (Fe,
  • the radioactive material will further comprise a bonding component suitable for covalent or non-covalent attachment to the substrate material, preferably being suitable for covalent attachment.
  • bifunctional chelates are covalently or otherwise bonded to the substrate material, preferably through an amine functional group bonded to the substrate material, which substrate material may include a siloxane coating, including an aliphatic hydrocyclosiloxane monomer coating, and the bifunctional chelate is then radiolabeled.
  • a variety of bifunctional chelates can be employed; most involve metal ion binding to thiolate groups, and may also involve metal ion binding to amide, amine or carboxylate groups.
  • bifunctional chelates include ethylenediamine tetraacetic acid (EDTA) , diethylenetetramine-pentaacedic acid (DTPA) , chelates of diamide-dimercaptides (N 2 S 2 ) / and variations on the foregoing, such as chelating compounds incorporating N 2 S 3 , N 2 S 4 and N 3 S 3 or other combinations of sulfur- and nitrogen- containing groups forming metal binding sites, and metallothionine . It is also possible, and contemplated, that a substrate material will be employed to which metal ions may be directly bonded to the substrate material, in which case the substrate material may include an amine functional group bonded to the surface of the substrate material .
  • the structure may optionally be sealed over at least a portion of its surface with a biocompatible material which is able to contain the radioactive material and prevent loss or leaching thereof, even when exposed to stressful in vivo conditions, such as elevated pH, elevated serum albumin levels, or the like.
  • a biocompatible material which is able to contain the radioactive material and prevent loss or leaching thereof, even when exposed to stressful in vivo conditions, such as elevated pH, elevated serum albumin levels, or the like.
  • a wide variety of sealing materials may be suitable, with biocompatible polymers, such as polyurethane, polyvinylchloride, polyethylene, and the like, being suitable. Particularly preferred are polyurethanes which may be dip- coated onto the surface of the device after the device has been coated with the radioactive material.
  • the sealant material will be formed over the device in a layer which is sufficiently thick to prevent or inhibit leaching or other loss of the radioactive material, typically being present in a very thin layer of 0.1 ml, or less.
  • a method for preparing a radioactive implantable structure comprises providing the device, generally as described above.
  • the method further comprises providing a radioactive material comprising the bonding constituent and the radioactive constituent, again generally as described above.
  • the specific activity of the radioactive material is then determined, either by calculation of the decay which will have occurred since preparation or by direct measurement .
  • An amount of the radioactive material is then bonded to the substrate material on the device in order to provide a predetermined radioactive dosage, typically in the range from 1 Gray to 250 Gray.
  • the dosage will usually be in the range from 1 Gray to 50 Gray, preferably in the range from 30 Gray to 50 Gray.
  • the dosage will usually be in the range from 10 Gray to 250 Gray, preferably being in the range from 25 Gray to 125 Gray.
  • a method for fabricating an implantable structure suitable for subsequent coating with a radioactive material comprises providing an implantable structure having a surface, generally as described above. At least a portion of the surface of the structure is then coated with a substrate material, generally as described above. Instructions are provided to coat the structure with a radioactive material which can bond to the substrate material .
  • a method for delivering a radioactive dose to a target location in a patient comprises providing an implantable structure having a surface, wherein at least a portion of the surface has been coated with a substrate material . A radioactive material is then bonded to the substrate, and the structure is then implanted at the target location.
  • the radioactive dose can be delivered for a variety of purposes, including intravascular delivery for the treatment of post-angioplasty and other hyperplasia, delivery to tumor and or neoplastic sites, and the like.
  • an implantable structure having a surface and being adapted for delivery to a target site in a patient's body is coated with the substrate materials over at least a portion of the surface, when the substrate material is capable of bonding to a radioactive material, typically by any of the mechanisms described above.
  • the structural component may comprise a stent, coil, wire, inflatable balloon, or any other device or structure which is capable of being implanted at a target location, including intravascular target locations, intraluminal target locations, target locations within solid tissue (typically for the treatment of tumors) , intrasynavial locations (e.g. for the treatment arthritis), and the like.
  • Such structures are suitable for radioactive coating by another, i.e., the substrate-coated structures will be a useful product in themselves.
  • At least a portion of the surface may optionally be sealed with a biocompatible material in order to inhibit leaching or other loss of the radioactive material upon subsequent introduction of the device to a patient.
  • a biocompatible material in order to inhibit leaching or other loss of the radioactive material upon subsequent introduction of the device to a patient.
  • the implantable structure can be used for permanent or temporary implantation, with exemplary devices including stents, coils, seeds, wires, inflatable balloons, catheters, probes, particles, beads, gels, and the like. Such structures may be delivered by or incorporated into intravascular and other medical catheters.
  • an implantable structure refers to virtually any device material, or substance which can be temporarily or permanently implanted into a human or animal host .
  • the structure can be implanted for a variety of purposes, including tumor treatment, treatment of cardiovascular disease, the treatment of lumenal blockages, and the like.
  • the presently preferred use is the treatment of hyperplasia in blood vessels which have been treated by conventional recanalization techniques, particularly intravascular recanalization techniques, such as angioplasty, atherectomy, and the like.
  • Non- biodegradable structures will be the most common, typically being comprised of physiologically compatible materials, such as metals, ceramics, and plastics having surfaces capable of being derivatized to attach the substrate material as described below.
  • Biodegradable structures will typically be formed from physiologically compatible biological and non- biological polymers, such as albumins, dextrans, polylactates, polyglycolates, and the like, which will typically persist after implantation for a time in the range from 1 day to 1 year, usually from 1 week to six months.
  • An exemplary non- biodegradable structures include stents, coils, wires, balloons, probes, catheters, needles, seeds, beads, and particles, while biodegradable structures will usually be in the form of seeds, beads, particles, and gels.
  • stents include intravascular stents, including both balloon-expandable stents and self-expanding stents.
  • Balloon-expandable stents are typically formed from a stainless steel are available from a number of commercial suppliers, most notably from Cordis under the Palmaz-Schatz tradename.
  • Self-expanding stents are typically composed from a shape memory alloy such as nitinol (nickel -titanium alloy) and are available from suppliers, such as Instent and Boston Scientific.
  • Fig. 1 illustrates a stent 10 which has been coated with a substrate material, as will be described in more detail below.
  • the stent 10 is typically composed of a stainless steel framework, in the case of balloon-expandable stents or from nickel titanium alloy, in the case of self- expanding stents. Both such structural frameworks are suitable for coating by the substrate material, as described below.
  • Exemplary structures also include balloons, such as balloon 22 on balloon catheter 20 (Fig. 2) .
  • balloons may also be coated with the substrate material according to the methods of the present invention.
  • the construction of intravascular balloon catheters is well known and amply described in the patent and medical literature.
  • the inflatable balloon 22 may be a non-distensible balloon, typically being composed of polyethyleneterephthalate, or may be an elastic balloon, typically being composed of latex or silicone rubber. Both these structural materials are suitable for coating with substrate materials according to the methods of the present invention.
  • Structures which may be coated also include beads, particles, and the like.
  • the beads and particles may themselves be non-degradable, e.g. being composed of metharcylates, styrene divinybenzene, or the like, or may be biodegradable, e.g. being composed of dextrans, albumins, polylactates, polyglycolates, or the like.
  • the implantable structures will have one or more surfaces which are coated with the substrate material.
  • stent 10 it is particularly desirable to coat the outer exposed surface of the individual elements of the stent framework.
  • the entire surface of the stent may be coated.
  • balloon 22 of catheter 20 it will be desirable to coat at least the outer cylindrical surface of the balloon 22 which will be in contact with the blood vessel when the balloon is inflated therein.
  • the substrate material includes the siloxane surface material described in U.S. Patent Nos. 5,338,770 and 5,463,010.
  • the siloxane material forms a smooth, continuous thin coating or membrane, and is produced as described in U.S. Patent Nos. 5,338,770 and 5,463,010.
  • the siloxane material coats the biomedical or implantable device, and a plurality of amine functional groups are bonded to the siloxane surface.
  • the metal ion may be bound directly to one or more of the amine groups. If an isotope of rhenium is employed, such as 186 Re or 188 Re, then the rhenium may be reduced to an appropriate redox state, using a stannous reducing agent or other reducing agents known in the art, to facilitate binding to the amine functional groups.
  • Polyamines can be used to increase the number of amines which are available for reaction or coupling.
  • Primary amines present on the structure as a result of the siloxane coating may be reacted with a polyamine, such as a "starburst" molecule as described in Newkome et al . (1992) Aldrichimica Acta 25:31-38, to increase the number of available amines.
  • a polyamine such as a "starburst" molecule as described in Newkome et al . (1992) Aldrichimica Acta 25:31-38
  • the degree of amplification will depend on the number of amines available on the polyamine, e.g. with starburst molecules having sixteen amines, the theoretical amplification is 15:1, although the actual amplification will be less because of steric hindrance and other inefficiencies.
  • the metal ion is bound to a bifunctional chelate, which directly or through a series of linking agents is in turn bound to the substrate material.
  • the siloxane material as above has bonded to its surface a plurality of amine functional groups. Covalently bonded to the amine functional groups are a plurality of poly (ethylene oxide) chains, such that a single poly (ethylene oxide) chain is bonded to a single amine functional group, all as is generally described in U.S. Patent No. 5,338,770.
  • a quantity of at least one molecule containing at least one reactive sulfide, or one disulfide bond, and a reactive amine is covalently bonded to the poly (ethylene oxide) chains.
  • a disulfide bond such as with a cystine
  • a stannous reducing agent may be employed to simultaneously reduce the disulfide bond in the bifunctional chelate, and to reduce the metal ion, such as an isotope of rhenium, to an approximate redox state for forming a stable bond.
  • the metal ion is then reacted with the reactive sulfide, which reactive sulfide is either originally present or formed through reduction of a disulfide bond, and the metal ion is bound to the reactive sulfides and available reactive amines, forming a metal ion complex.
  • Means to attach or complex disulfide bonds, and chelating agents and substrates containing disulfide bonds, are known to those skilled in the art.
  • Disulfide bonds may be introduced into such proteins by chemical methods involving direct conjugation. Chemical means used to introduce disulfide bonds into proteins include use of homofunctional crosslinkers and heterofunctional crosslinkers .
  • Representative chemicals which can be used to introduce disulfide bonds include 4 -succinimidyloxycarbonyl -alpha-methyl- alpha- (2-pyridyldithiol) -toluene; N-succinimidyl 3- (2-pyridyl- dithio) propionate; sulfosuccinimidyl 6- [3- (2-pyridiyldithiol) propinoamido] hexonate; dithioiiis (succinimidylproprionate) ;
  • bifunctional chelating agents covalently or otherwise bonded to the substrate material, in one embodiment through an amine functional group bonded to the substrate material, which substrate material may include a siloxane coating, including an aliphatic hydrocyclosiloxane monomer coating as described above.
  • Representative bifunctional chelating agents include agents based on aminocarboxylic acids, such as EDTA and cyclic anhydride of DTPA; agents based on triamines, including those disclosed in U.S. Patent No. 5,101,041; and thiol-containing agents, including the agents disclosed in U.S. Patent Nos. 5,443,815 and 5,382,654.
  • the bifunctional chelating agent may also be a peptide sequence, composed of natural or unnatural amino acids, covalently or otherwise bonded to the substrate material, including through functional amine groups bonded to the substrate material.
  • Representative peptide sequence bifunctional chelating agents including the amino acid sequences :
  • the implantable structure may be radiolabeled by means known to the art.
  • the structure is placed in a solution containing the radionuclide, reducing agents as required to reduce the radionuclide and disulfide bonds, if present, including stannous reducing agents, appropriate buffers and the like.
  • the solution with the device may be heated to any temperature up to boiling temperature, and may be incubated for any required period.
  • the amount of radioactivity bonded to the implantable device may be controlled by varying the concentration of radioactivity in the solution, by varying the reaction conditions, including pH, temperature and the length of incubation, and/or by controlling or limiting the amount of surface to which the radiovuclide is bound.
  • Re- 188 and Y-90 are two beta-emittors which are particularly useful.
  • Re-188 has some significant advantages as a radionuclide.
  • the availability of a generator system is a considerable advantage as it allows for cost-effective on-site access to the radionuclide over a period of months.
  • the generator system may be similar to the Mo-99/Tc-99m generator system widely used in nuclear medicine.
  • Re-188 in the form of perrhenate is eluted from the generator using oxidant-free 0.9% NaCl .
  • Y-90 is also available from a generator system composed of the Sr-90/Y-90 pair of radionuclides and can be chelated by a number of heterocyclic chelates such as 1,4,8, ll-tetraazacyclotetradecane-N,N' , N" ,N" ' -tetraacetic acid (TETA) or 1 , 4 , 7, 10-tetraazacyclododecane-N,N' ,N" ,N" ' - tetraacetic acid (DOTA) .
  • DOTA is recognized as a superior Y- 90 chelator.
  • the device After coating the surface of the structure with the radioactive material, the device will preferably be sealed in order to inhibit or prevent accidental leakage or other loss of the radioactive material when the device is introduced and/or implanted into the patient.
  • the sealing step may take a variety of forms.
  • the material will be a biocompatible polymer, such as a polyurethane, polyvinyl chloride, polyethylene, or the like, and will be applied to the device by dip-coating.
  • the polymer will usually be present in a solvent which permits rapid air drying .
  • the sealing layer could applied by a variety of other techniques, such as shrink-wrapping of a thin sheath of polymeric material, chemical vapor deposition of a variety of materials, electrolis coating of certain bio-compatible metals (which will be useful with metallic substrates, such as stents, radioactive seeds, and the like), and the like.
  • the sealant layers will protect the underlying layers of radioactive material against interaction with the physical and chemical conditions in which the device is to be implanted.
  • Other structures may be introduced by open surgical procedures, endoscopic procedures, injection (in the case of beads, particles, and gels), and the like.
  • the radioactively coated devices may then be introduced to the patient in a conventional manner, depending on the device.
  • the stent will be delivered by a stent delivery catheter, typically an intravascular balloon catheter in the case of balloon-expanded stents or a containment catheter in the case of self-expanding stents.
  • the delivery catheters may be modified to provide for shielding of the radioactive stent, and methods for constructing shielded catheters are well described in the patent literature.
  • Other structures may be introduced by open surgical procedures, endoscopic procedures, injection (in the case of beads, particles, and gels), and the like.
  • the radioactively coated balloon catheter 20 may also be delivered to the patient in a generally conventional manner.
  • the catheter may be introduced through the femoral artery using the Seldinger technique.
  • the catheter will typically be guided to the coronary os using a guiding catheter and thereafter within a target coronary artery under fluoroscopy.
  • the balloon will then be inflated in order to engage the radioactive material directly against the inner wall of the blood vessel.
  • the balloon may remain inflated for extended periods of time in the case of perfusion balloons. In the case of non-perfusion balloons, it will be necessary to periodically deflate the balloon in order to permit blood perfusion to the distal coronary arteries. The total time of balloon exposure will depend on the dosage.
  • Fig. 3 illustrates an implantable stent 10 which has been coated with the substrate material, but which has not yet been coated with the radioactive material.
  • the stent 10 will be packaged inside a suitable medical device package, such as pouch 30, and instructions for use ("IFU") will be provided with, within or on the pouch 30.
  • IFU instructions for use
  • the instructions for use describe coating of the stent 10 with the radioactive material according to any of the methods of the present invention described above.
  • a radioactively coated stent 110 is illustrated in Fig. 4.
  • Stent 110 comprises a stent structure 112, typically in the form of a metal coil, scaffold, or other conventional device intended for balloon expansion or self-expansion within a blood vessel or other body lumen.
  • the stent structure 112 will be first coated with a substrate layer and radioactive material, shown collectively as 114 in Fig. 4. Then, according to the present invention, the radioactive stent is sealed with a layer 116, typically a polymeric layer which is dip-coated onto the stent, also described above.
  • Fig. 5 illustrates an implantable stent 112 which has been coated with the substrate material, but which has not yet been coated with the radioactive material or the sealing coating or layer.
  • the stent 112 will be packaged inside a suitable medical device package, such as pouch 40, and instructions for use IFU 30 will be provided within or on the pouch 30.
  • the sealing material and/or other reagent (s) may be provided in a vial 20 as part of the kit, but usually the radioactive material will not be provided, and instead will be supplied by the user from a separate central source as discussed above.
  • the instructions for use describe coating of the stent 112 with the radioactive material according to any of the methods of the present invention described above.
  • Example 1 Attachment of the S-protected chelate benzoyl - mercaptoacetyl triglycine (bnz-MAG3) to a stainless steel stent .
  • Stainless steel stents are activated by a plasma process using a mixture of oxygen and ammonia gas resulting in ammonia becoming annealed to stainless steel stent surface.
  • the activated stent surface is further coated using a secondary plasma-coating resulting in the deposition of a tetra-methyl-cyclo-tetra-siloxane polymer.
  • the siloxane polymer is bonded to the stent via a nitrogen bridge.
  • the free siloxane surface of the coated stent is reacted with N-tetramethyl silylallyl-amine resulting in a layer of free amine groups on the outside of the stent.
  • bnz-MAG3- succimimide ester is then reacted with the amines on the stent in an aqueous buffer containing 0.1 M sodium bicarbonate, pH 8.5, for 15 minutes.
  • the unreacted bnz-MAG3 is then rinsed in water and dried under a stream of nitrogen. This results in covalent attachment of bnz-MAG3 to the stent via a peptide linkage.
  • the stent labeling kit is a self-contained kit containing all of the components needed to radiolabel stents on site except the radioactive material.
  • the key component is one or more chelate-coated stents in a sealed labeling vessel.
  • the kit would contain three vials:
  • a vial containing a stent and a lyophilized formulation of buffer and stannous salts b) a vial containing a suitable polymeric sealant (e.g. ticoflex) solubilized in ethanol , c) a vial containing ethanol (200 proof, USP) for rinsing, and d) a package insert with detailed labeling and use instructions .
  • a suitable polymeric sealant e.g. ticoflex
  • the first vial would contain a lyophilized formulation of stannous tartrate and Na-K-tartrate such that upon hydration to a final volume of 1 ml the solution would contain 5 mM Na-K-tartrate, pH 4.5, and 0.1 mM stannous tartrate.
  • Stannous ions are used to chemically reduce Re-188 (VII) to a reactive Re-188 (V).
  • the Na-K-tartrate used as a complexing agent to transfer Re-188 (V) to the chelate on the stent.
  • the second vial contains ticoflex solubilized in ethanol and is used to fix and seal the Re-188 to stent, and should result in a 10-100 nm coating of the stent and its associated radioactivity.
  • the third vial contains ethanol used as a rinse solution after the labeling but before sealing, and after sealing. In the first rinse it removes water and in the second rinse it removes unbound ticoflex.
  • the kit will be designed to be used as follows: To first vial (a) will be added Re-188 in the form of Re-188- perrhenate in 0.9% NaCl introduced by use of a needle and syringe. The vial will be incubated in a boiling water bath for 15 minutes.
  • the solution will be withdrawn and the stent washed in situ serially with water and then ethanol.
  • An aliquot of the ticoflex solution will be introduced to the vial sufficient to completely cover the stent.
  • the vial will be immediately flushed with ethanol and then water.
  • the stent will then be dried in situ under a stream of sterile, medical grade nitrogen.

Landscapes

  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Des structures implantables, tels que des extenseurs implantés de manière permanente et des cathéters à ballonnet implantés temporairement, sont recouvertes d'une matière radioactive. Au moins une partie d'une surface de la structure est d'abord enduite d'une première matière formant substrat. La matière dose radioactive est ensuite liée à la matière formant substrat sur la surface de la structure. La quantité de matière radioactive liée au substrat peut être choisie de sorte que la radioactive requise soit produite pour un traitement intravasculaire, antitumoral ou un autre protocole thérapeutique. Eventuellement, au moins une partie de la matière radioactive liée est recouverte d'une couche de scellement.
PCT/US1998/014489 1997-07-11 1998-07-10 Procedes et systemes pour la preparation et le scellage de structures produisant un rayonnement WO1999002194A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP98934491A EP0998309A1 (fr) 1997-07-11 1998-07-10 Procedes et systemes pour la preparation et le scellage de structures produisant un rayonnement
JP2000501784A JP2001509493A (ja) 1997-07-11 1998-07-10 放射送達構造体の調製およびシール化のための方法およびシステム
AU83999/98A AU8399998A (en) 1997-07-11 1998-07-10 Methods and systems for preparing and sealing radiation delivery structures

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5237097P 1997-07-11 1997-07-11
US60/052,370 1997-07-11
US8025198P 1998-04-01 1998-04-01
US60/080,251 1998-04-01

Publications (1)

Publication Number Publication Date
WO1999002194A1 true WO1999002194A1 (fr) 1999-01-21

Family

ID=26730530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/014489 WO1999002194A1 (fr) 1997-07-11 1998-07-10 Procedes et systemes pour la preparation et le scellage de structures produisant un rayonnement

Country Status (4)

Country Link
EP (1) EP0998309A1 (fr)
JP (1) JP2001509493A (fr)
AU (1) AU8399998A (fr)
WO (1) WO1999002194A1 (fr)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0819446A3 (fr) * 1996-07-19 2000-01-26 Advanced Cardiovascular Systems, Inc. Méthode radiothérapeutique et dispositif plus particulièrement destiné à être implanté
WO2000057956A1 (fr) * 1999-03-26 2000-10-05 Implant Sciences Corporation Procede de fabrication de dispositifs medicaux radioactifs
EP0963182A4 (fr) * 1996-09-26 2000-10-18 Univ Columbia Procede pour traiter un processus pathologique dans une structure luminale
EP1103234A1 (fr) * 1999-11-23 2001-05-30 SORIN BIOMEDICA CARDIO S.p.A. Appareil , méthode et kit pour transférer des agents radioactifs sur des stents d' angioplastie
EP1208874A1 (fr) * 2000-11-17 2002-05-29 MDS Nordion Inc. Dispositif médical radioactif pour la radiothérapie
EP1149592A3 (fr) * 2000-04-28 2004-05-19 MDS Nordion Inc. Dispositifs à revêtement radioactif
US6918924B2 (en) 2000-04-06 2005-07-19 Innercool Therapies, Inc. Method and apparatus for regulating patient temperature by irrigating the bladder with a fluid
US8834837B2 (en) 2003-04-30 2014-09-16 Ramot At Tel-Aviv University Ltd. Method and device for radiotherapy
US9809623B2 (en) 2014-10-01 2017-11-07 Protagonist Therapeutics, Inc. α4β7 peptide monomer and dimer antagonists
US9822157B2 (en) 2013-03-15 2017-11-21 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
US10023614B2 (en) 2014-07-17 2018-07-17 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US10059744B2 (en) 2014-05-16 2018-08-28 Protagonist Therapeutics, Inc. α4β7 thioether peptide dimer antagonists
WO2018207105A1 (fr) * 2017-05-11 2018-11-15 Alpha Tau Medical Ltd. Revêtements polymères pour dispositifs de brachythérapie
US10278957B2 (en) 2017-09-11 2019-05-07 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
US10407468B2 (en) 2016-03-23 2019-09-10 Protagonist Therapeutics, Inc. Methods for synthesizing α4β7 peptide antagonists
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CN111888639A (zh) * 2020-09-07 2020-11-06 郑州大学第一附属医院 放射粒子装载器
US11041000B2 (en) 2019-07-10 2021-06-22 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US11472842B2 (en) 2015-12-30 2022-10-18 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
US11753443B2 (en) 2018-02-08 2023-09-12 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
US11845808B2 (en) 2020-01-15 2023-12-19 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US11857803B2 (en) 2020-12-16 2024-01-02 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy with enhanced beta treatment
US11939361B2 (en) 2020-11-20 2024-03-26 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of Interleukin-23 receptor
US11969485B2 (en) 2018-04-02 2024-04-30 Alpha Tau Medical Ltd. Controlled release of radionuclides
US12018057B2 (en) 2020-01-15 2024-06-25 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273093B2 (en) * 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
US20140294902A1 (en) * 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3127313A (en) * 1964-03-31 Method of making a radioactive
US3974322A (en) * 1972-02-16 1976-08-10 Lidia Emelianovna Drabkina Radioactive source
US4167179A (en) * 1977-10-17 1979-09-11 Mark Kirsch Planar radioactive seed implanter
US4478914A (en) * 1980-01-24 1984-10-23 Giese Roger W Process for applying multiple layers of a protein and a ligand extender to a surface and to the multiple-layer system
US4595599A (en) * 1985-06-21 1986-06-17 Advanced Chemical Technologies Company Luminescent silane
US5342283A (en) * 1990-08-13 1994-08-30 Good Roger R Endocurietherapy
US5567408A (en) * 1992-02-20 1996-10-22 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
US5593658A (en) * 1992-09-04 1997-01-14 The General Hospital Corporation Medical compositions
US5614652A (en) * 1991-01-07 1997-03-25 Syngenix Limited Particulates

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3127313A (en) * 1964-03-31 Method of making a radioactive
US3974322A (en) * 1972-02-16 1976-08-10 Lidia Emelianovna Drabkina Radioactive source
US4167179A (en) * 1977-10-17 1979-09-11 Mark Kirsch Planar radioactive seed implanter
US4478914A (en) * 1980-01-24 1984-10-23 Giese Roger W Process for applying multiple layers of a protein and a ligand extender to a surface and to the multiple-layer system
US4478914B1 (en) * 1980-01-24 1997-06-17 Roger W Giese Process for applying multiple layers of a protein and a ligand extender to a surface and to the multiple layer system
US4595599A (en) * 1985-06-21 1986-06-17 Advanced Chemical Technologies Company Luminescent silane
US5342283A (en) * 1990-08-13 1994-08-30 Good Roger R Endocurietherapy
US5614652A (en) * 1991-01-07 1997-03-25 Syngenix Limited Particulates
US5567408A (en) * 1992-02-20 1996-10-22 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
US5593658A (en) * 1992-09-04 1997-01-14 The General Hospital Corporation Medical compositions

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0819446A3 (fr) * 1996-07-19 2000-01-26 Advanced Cardiovascular Systems, Inc. Méthode radiothérapeutique et dispositif plus particulièrement destiné à être implanté
EP0963182A4 (fr) * 1996-09-26 2000-10-18 Univ Columbia Procede pour traiter un processus pathologique dans une structure luminale
US6306073B1 (en) 1996-09-26 2001-10-23 The Trustees Of Columbia University In The City Of New York Apparatus and method for treating a disease process in a luminal structure with a radionuclide and chelating agent
WO2000057956A1 (fr) * 1999-03-26 2000-10-05 Implant Sciences Corporation Procede de fabrication de dispositifs medicaux radioactifs
EP1103234A1 (fr) * 1999-11-23 2001-05-30 SORIN BIOMEDICA CARDIO S.p.A. Appareil , méthode et kit pour transférer des agents radioactifs sur des stents d' angioplastie
US6447439B1 (en) 1999-11-23 2002-09-10 Sorin Biomedica Cardio S.P.A. Device for conveying radioactive agents on angioplasty stents, respective method and kit
US6585632B2 (en) 1999-11-23 2003-07-01 Sorin Biomedica Cardio S.P.A. Device for conveying radioactive agents on angioplasty stents, respective method and kit
US6918924B2 (en) 2000-04-06 2005-07-19 Innercool Therapies, Inc. Method and apparatus for regulating patient temperature by irrigating the bladder with a fluid
EP1149592A3 (fr) * 2000-04-28 2004-05-19 MDS Nordion Inc. Dispositifs à revêtement radioactif
EP1208874A1 (fr) * 2000-11-17 2002-05-29 MDS Nordion Inc. Dispositif médical radioactif pour la radiothérapie
US10058713B2 (en) 2003-04-30 2018-08-28 Alpha Tau Medical Ltd. Method and device for radiotherapy
US8894969B2 (en) 2003-04-30 2014-11-25 Althera Medical Ltd. Method and device for radiotherapy
US8834837B2 (en) 2003-04-30 2014-09-16 Ramot At Tel-Aviv University Ltd. Method and device for radiotherapy
US11807674B2 (en) 2013-03-15 2023-11-07 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
US10501515B2 (en) 2013-03-15 2019-12-10 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
US9822157B2 (en) 2013-03-15 2017-11-21 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
US10030061B2 (en) 2013-03-15 2018-07-24 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
US10442846B2 (en) 2013-03-15 2019-10-15 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
US10059744B2 (en) 2014-05-16 2018-08-28 Protagonist Therapeutics, Inc. α4β7 thioether peptide dimer antagonists
US10626146B2 (en) 2014-05-16 2020-04-21 Protagonist Therapeutics, Inc. α4β7 thioether peptide dimer antagonists
US11840581B2 (en) 2014-05-16 2023-12-12 Protagonist Therapeutics, Inc. α4β7 thioether peptide dimer antagonists
US10023614B2 (en) 2014-07-17 2018-07-17 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US10196424B2 (en) 2014-07-17 2019-02-05 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US10941183B2 (en) 2014-07-17 2021-03-09 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US10035824B2 (en) 2014-07-17 2018-07-31 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US11884748B2 (en) 2014-07-17 2024-01-30 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
US9809623B2 (en) 2014-10-01 2017-11-07 Protagonist Therapeutics, Inc. α4β7 peptide monomer and dimer antagonists
US11111272B2 (en) 2014-10-01 2021-09-07 Protagonist Therapeutics, Inc. α4α7 peptide monomer and dimer antagonists
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US11472842B2 (en) 2015-12-30 2022-10-18 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
US10407468B2 (en) 2016-03-23 2019-09-10 Protagonist Therapeutics, Inc. Methods for synthesizing α4β7 peptide antagonists
US11529432B2 (en) 2017-05-11 2022-12-20 Alpha Tau Medical Ltd. Polymer coatings for brachytherapy devices
WO2018207105A1 (fr) * 2017-05-11 2018-11-15 Alpha Tau Medical Ltd. Revêtements polymères pour dispositifs de brachythérapie
US10729676B2 (en) 2017-09-11 2020-08-04 Protagonist Theraputics, Inc. Opioid agonist peptides and uses thereof
US10278957B2 (en) 2017-09-11 2019-05-07 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
US11753443B2 (en) 2018-02-08 2023-09-12 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
US11969485B2 (en) 2018-04-02 2024-04-30 Alpha Tau Medical Ltd. Controlled release of radionuclides
US11041000B2 (en) 2019-07-10 2021-06-22 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US11845808B2 (en) 2020-01-15 2023-12-19 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US12018057B2 (en) 2020-01-15 2024-06-25 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CN111888639A (zh) * 2020-09-07 2020-11-06 郑州大学第一附属医院 放射粒子装载器
US11939361B2 (en) 2020-11-20 2024-03-26 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of Interleukin-23 receptor
US11857803B2 (en) 2020-12-16 2024-01-02 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy with enhanced beta treatment

Also Published As

Publication number Publication date
AU8399998A (en) 1999-02-08
EP0998309A1 (fr) 2000-05-10
JP2001509493A (ja) 2001-07-24

Similar Documents

Publication Publication Date Title
EP0998309A1 (fr) Procedes et systemes pour la preparation et le scellage de structures produisant un rayonnement
US6264596B1 (en) In-situ radioactive medical device
US5707332A (en) Apparatus and method to reduce restenosis after arterial intervention
EP1149592B1 (fr) Dispositifs à revêtement radioactif
US6152869A (en) Radioactive stent and process for preparation thereof
US6248057B1 (en) Absorbable brachytherapy and chemotherapy delivery devices and methods
CA2323440A1 (fr) Composition pouvant etre radioactivee convenant pour la fabrication de dispositifs medicaux implantables
US6461666B2 (en) Radioactive balloon for dilation catheter system and process for preparation thereof
EP0963182A1 (fr) Procede pour traiter un processus pathologique dans une structure luminale
CA2285324A1 (fr) Therapie ciblee et dirigee sur un dispositif biomedical
JP2002502638A (ja) 軟ｘ線を放射する医療器具
US8834338B2 (en) Dosimetry implant for treating restenosis and hyperplasia
US6238872B1 (en) Targeted therapy to a biomedical device
EP0894012A2 (fr) Systeme de radiotherapie locale
US6045495A (en) Apparatus and method to treat a disease process in a luminal structure
WO1999051299A2 (fr) Composition pouvant etre radioactivee convenant pour la fabrication de dispositifs medicaux implantables
US6409943B1 (en) In-situ-generated solid radiation source based on Tungsten 188 /Rhenium 188 and use thereof
US6500108B1 (en) Radiation delivery system and method
Zamora et al. Radiolabeling brachytherapy sources with re‐188 through chelating microfilms: Stents
GB2352635A (en) Medical stents
Waksman Progress in clinical trials for coronary arterial restenosis using beta radiation sources
JP2004531302A (ja) 放射性被覆ステント
Knapp et al. Use of Reactor-Produced Radioisotopes for Prevention Restenosis After Angioplasty
MXPA99008952A (en) Targeted therapy to a biomedical device
JP2000140127A (ja) 放射性ステント

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998934491

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998934491

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1998934491

Country of ref document: EP